A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2018
At a glance
- Drugs ABX 464 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Abivax
- 21 Dec 2017 Status changed from not yet recruiting to recruiting.
- 18 Dec 2017 New trial record